Establishment of a novel method to assess MEK1/2 inhibition in PBMCs for clinical drug development.

Schüssele, Lara M; Koch-Heier, Julia; Volk, Julian; Löffler, Markus W; Hoffmann, Katharina; Bruyns, Regina M; Planz, Oliver

Schüssele, Lara M; Koch-Heier, Julia; Volk, Julian; Löffler, Markus W; Hoffmann, Katharina; Bruyns, Regina M; Planz, Oliver.

Afiliação

Schüssele LM; Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Koch-Heier J; Atriva Therapeutics GmbH, Tübingen, Germany.
Volk J; Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Löffler MW; Atriva Therapeutics GmbH, Tübingen, Germany.
Hoffmann K; Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Bruyns RM; Atriva Therapeutics GmbH, Tübingen, Germany.
Planz O; Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.

Front Cell Dev Biol ; 10: 1063692, 2022.

Article em En | MEDLINE | ID: mdl-36578787

Palavras-chave

MEK1/2 inhibitor; PBMCs; clinical drug development; pharmacodynamics; zapnometinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Front Cell Dev Biol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google